Vivos Therapeutics' VIDASLEEP Receives CMS PDAC Approval

Summary

Vivos Therapeutics Inc’s VIDASLEEP oral appliance has received CMS PDAC approval.Reuters

Impact Analysis

The event is classified at the company level, specifically affecting Vivos Therapeutics. The CMS PDAC approval is a significant milestone for the company as it allows the VIDASLEEP device to be potentially covered under Medicare, expanding its market reach. First-order effects include increased sales potential and enhanced market credibility. Second-order effects might involve competitive positioning within the sleep apnea treatment market and potential partnerships or acquisitions. Investment opportunities could arise from increased stock valuation due to anticipated revenue growth and expanded market access.Reuters